Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial

Abroad (travel likely)RecruitingPHASE4

Conditions

SARS CoV-2 Post-Acute Sequelae

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Kingston Health Sciences Centre, Kingston, Ontario, Canada
Contact: Study coordinator (Dr. Siddhartha Srivastava) · srivastava.s@queensu.ca · 613-533-2780
Niagara Health System, St. Catharines, Ontario, Canada
Contact: Study coordinator (Dr. Jennifer Tsang) · jennifer.tsang@niagarahealth.on.ca · 905-684-7271
Mount Sinai Hospital, Sinai Health System, Toronto, Ontario, Canada
Contact: Study coordinator (Dr. Kieran Quinn) · kieran.quinn@mail.utoronto.ca · 416-843-8403
Contact: Principal Investigator (Dr. Kieran Quinn)
Dr. Mike Fralick (Sub-investigator)
St. Joseph's Health Centre, Unity Health Toronto, Toronto, Ontario, Canada
Contact: Study coordinator (Dr. Travis Carpenter) · travis.carpenter@unityhealth.to · 416-530-6692
Contact: Principal Investigator (Dr. Travis Carpenter)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) Infection

SARS CoV-2 Post-Acute Sequelae

Abroad (travel likely)RecruitingEARLY_PHASE1

Birmingham, United States